Biogen Inc. (LON:0R1B)
London · Delayed Price · Currency is GBP · Price in USD 142.49
+0.61 (0.43%)
At close: Sep 8, 2025
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
959.48K GBP
Profits / Employee
146.89K GBP
Market Cap
15.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7,605 | 35 | 0.46% |
| Dec 31, 2023 | 7,570 | -1,155 | -13.24% |
| Dec 31, 2022 | 8,725 | -885 | -9.21% |
| Dec 31, 2021 | 9,610 | 510 | 5.60% |
| Dec 31, 2020 | 9,100 | 1,700 | 22.97% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Genus | 3,500 |
Biogen News
- 4 days ago - Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News - GuruFocus
- 5 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 5 days ago - Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
- 5 days ago - Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector - GuruFocus
- 5 days ago - Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
- 5 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Benzinga
- 5 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - GlobeNewsWire
- 6 days ago - Stocks making the biggest midday moves: Frontier Group, Kraft Heinz, Biogen and more - CNBC